To Asses the Immunogenicity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Too see percentage of subjects with HI titer >= 1:40, 28 days after two doses in infants and children (6 months-8 years old) and one dose in children 9-11 years old for each strain.

Inclusion Criteria:

• Healthy
• Parents have been informed properly regarding the study and signed the informed consent form
• Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial

Exclusion Criteria:

• Subjects concomitantly enrolled or scheduled to be enrolled in another trial
• Evolving mild, moderate, or severe illness, especially infectious diseases or fever (axillary temperature >=37oC)
• Known history of allergy to egg and/or chicken protein or any other component of the vaccines
• Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection
• Subject who has received a treatment likely to alter the immune response in the previous 4 weeks (intravenous immunoglobulins, blood-derived products or long term corticotherapy (>2 weeks)).
• Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives.
• Subjects has been immunized with influenza vaccine within 1 year
• Subjects receives any vaccination within 1 months before and after immunization of Flubio.